{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:46:57Z","timestamp":1790297217390,"version":"4.1.0"},"reference-count":28,"publisher":"BMJ","issue":"9","license":[{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"unspecified","delay-in-days":28,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Fundaci\u00f3n Mundo Sano, Argentina"},{"DOI":"10.13039\/501100014054","name":"Drugs for Neglected Diseases initiative","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Laboratorio ELEA Phoenix S.A."}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2025,9,8]]},"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>Chagas disease (CD) is one of the most neglected diseases in the world. In Latin America, CD is endemic in 21 countries, with an estimated 70\u2009million people at risk of infection. Current treatments are limited to two nitroheterocyclic compounds: nifurtimox and benznidazole (BZN). Each has significant limitations, including long duration and safety concerns. However, data from recently completed studies suggest that reduced-duration regimens may be equally effective while enhancing safety.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and analysis<\/jats:title>\n                  <jats:p>NuestroBen is a phase III, randomised, multicentre clinical trial designed to assess whether shorter (2- and 4-week) regimens of BZN are non-inferior to the standard 8-week treatment. A total of 540 adult participants with no evidence of organ damage (the indeterminate form) or with mild cardiac progression (mild electrocardiographic alterations and without systolic dysfunction or symptoms), all in the chronic phase of CD, will be recruited at six study sites in Argentina and two study sites in Bolivia. Participants will be randomised to receive one of the two shortened regimens of BZN (300\u2009mg per day for 2 or 4 weeks) or standard treatment (300\u2009mg per day for 8 weeks). The primary endpoint is sustained elimination of parasitaemia from the end of treatment through 12 months of follow-up. Secondary endpoints will assess sustained clearance of parasitaemia at 1, 4, 6 and 8 months of follow-up from the end of treatment, drug tolerability and adherence to treatment. NuestroBen will also evaluate whether two shortened regimens of BZN improve drug tolerability and treatment adherence compared with the current standard treatment while maintaining efficacy in participants with the indeterminate form of CD or with mild cardiac involvement.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Ethics and dissemination<\/jats:title>\n                  <jats:p>In Argentina, this study was approved by <jats:italic>Fundaci\u00f3n de Estudios Farmacol\u00f3gicos y Medicamentos \u2018Luis M. Zieher\u2019<\/jats:italic> for its conduct at the <jats:italic>Instituto de Cardiolog\u00eda de Corrientes \u2018Juana Francisca Cabral\u2019<\/jats:italic> (reference: NuestroBen-2020\/2021) and the <jats:italic>Instituto Nacional de Parasitolog\u00eda \u2018Dr. Mario Fatala Chaben\u2019<\/jats:italic> (reference: NuestroBen-2020\/2021) by <jats:italic>Comit\u00e9 Institucional de \u00c9tica de Investigaci\u00f3n en Salud<\/jats:italic> for the <jats:italic>Centro de Chagas y Patolog\u00eda Regional de Santiago del Estero<\/jats:italic> (reference: NuestroBen-2020-088\/2021), by <jats:italic>Comit\u00e9 de \u00c9tica en Investigaci\u00f3n<\/jats:italic> for the <jats:italic>Hospital de Infecciosas F.J. Mu\u00f1iz<\/jats:italic> (reference: NuestroBen-2020\u20134037) and the <jats:italic>Hospital General de Agudos D.F. Santojanni<\/jats:italic> (reference: NuestroBen-2020\u20134039) and by <jats:italic>Comit\u00e9 de Bio\u00e9tica<\/jats:italic> for the <jats:italic>Fundaci\u00f3n Hu\u00e9sped<\/jats:italic> (reference: NuestroBen-2020\/2021). In Bolivia, it was approved by <jats:italic>Comit\u00e9 de \u00c9tica en Investigaci\u00f3n en Salud<\/jats:italic> from the <jats:italic>Universidad Aut\u00f3noma Juan Misael Saracho<\/jats:italic> (reference: NuestroBen-2020\/2025). All participants are asked to provide written informed consent to participate. Recruitment processes started in July 2023, and as of 15 June 2025, 140 participants have been recruited. Findings will be shared with Argentinian and Bolivian public health officials and with the Chagas and tropical medicine communities via international conferences. Findings will also be published in medical journals.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trial registration number<\/jats:title>\n                  <jats:p>\n                     <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT04897516\">NCT04897516<\/jats:ext-link>.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjopen-2024-098079","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T09:16:25Z","timestamp":1759223785000},"page":"e098079","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["New regimens of benznidazole for the treatment of chronic Chagas disease in adult participants in indeterminate form or with mild cardiac progression (NuestroBen study): protocol for a phase III randomised, multicentre non-inferiority clinical trial"],"prefix":"10.1136","volume":"15","clinical-trial-number":[{"clinical-trial-number":"nct04897516","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03378661","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06339710","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7994-4511","authenticated-orcid":false,"given":"Tayn\u00e1","family":"Marques","sequence":"first","affiliation":[{"name":"Drugs for Neglected Diseases initiative, Rio de Janeiro, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1481-8367","authenticated-orcid":false,"given":"Colin","family":"Forsyth","sequence":"additional","affiliation":[{"name":"Drugs for Neglected Diseases initiative, Rio de Janeiro, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiana","family":"Barreira","sequence":"additional","affiliation":[{"name":"Drugs for Neglected Diseases initiative, Rio de Janeiro, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carola","family":"Lombas","sequence":"additional","affiliation":[{"name":"Laboratorio ELEA Phoenix S.A, Buenos Aires, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7234-5213","authenticated-orcid":false,"given":"Bethania","family":"Blum de Oliveira","sequence":"additional","affiliation":[{"name":"Drugs for Neglected Diseases initiative, Rio de Janeiro, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00f3nica","family":"Laserna","sequence":"additional","affiliation":[{"name":"Drugs for Neglected Diseases initiative, Rio de Janeiro, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Israel","family":"Molina","sequence":"additional","affiliation":[{"name":"International Health Unit Vall d'Hebron-Drassanes, Infectious Diseases Department, Vall d\u2019Hebron University Hospital, Barcelona, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain"},{"name":"Funda\u00e7\u00e3o Oswaldo Cruz, Belo Horizonte, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria del Carmen","family":"Bangher","sequence":"additional","affiliation":[{"name":"Instituto de Cardiolog\u00eda de Corrientes \u2018Juana Francisca Cabral\u2019, Corrientes, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosmiro","family":"Javier Fern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Centro de Chagas y Patolog\u00eda Regional, Hospital Independencia, Santiago del Estero, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Lloveras","sequence":"additional","affiliation":[{"name":"Hospital de Infecciosas Dr. Francisco Javier Mu\u00f1iz, Buenos Aires, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marisa Liliana","family":"Fern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Instituto Nacional de Parasitolog\u00eda \u2018Dr. Mario Fatala Chaben\u2019, Buenos Aires, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Scapellato","sequence":"additional","affiliation":[{"name":"Hospital Donaci\u00f3n Francisco Santojanni, Buenos Aires, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Patterson","sequence":"additional","affiliation":[{"name":"Fundaci\u00f3n Hu\u00e9sped, Buenos Aires, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilson","family":"Garcia","sequence":"additional","affiliation":[{"name":"Centro de Investigaci\u00f3n en Enfermedades Transmitidas por Vectores-SEDES Chuquisaca, Sucre, Bolivia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lourdes","family":"Ortiz","sequence":"additional","affiliation":[{"name":"Plataforma de Atenci\u00f3n Integral a los Pacientes con Enfermedad de Chagas, Tarija, Bolivia"},{"name":"Universidad Aut\u00f3noma Juan Misael Saracho, Tarija, Bolivia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Schijman","sequence":"additional","affiliation":[{"name":"Laboratorio de Biolog\u00eda Molecular de la Enfermedad de Chagas, Instituto de Investigaciones en Ingenier\u00eda Gen\u00e9tica y Biolog\u00eda Molecular Dr. H\u00e9ctor N Torres(INGEBI), Consejo Nacional de Investigaciones Cient\u00edficas y T\u00e9cnicas (CONICET), Buenos Aires, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Otacilio C","family":"Moreira","sequence":"additional","affiliation":[{"name":"Laborat\u00f3rio de Virologia e Parasitologia Molecular, Instituto Oswaldo Cruz, Funda\u00e7\u00e3o Oswaldo Cruz, Rio de Janeiro, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lineth","family":"Garc\u00eda","sequence":"additional","affiliation":[{"name":"Instituto de Investigaciones Biom\u00e9dica (IIBISMED), Universidad Mayor de San Simon, Cochabamba, Bolivia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kert","family":"Viele","sequence":"additional","affiliation":[{"name":"Berry Consultants, LLC, Austin, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Longhi","sequence":"additional","affiliation":[{"name":"Laboratorio de Biolog\u00eda Molecular de la Enfermedad de Chagas, Instituto de Investigaciones en Ingenier\u00eda Gen\u00e9tica y Biolog\u00eda Molecular Dr. H\u00e9ctor N Torres(INGEBI), Consejo Nacional de Investigaciones Cient\u00edficas y T\u00e9cnicas (CONICET), Buenos Aires, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Vaillant","sequence":"additional","affiliation":[{"name":"Luxembourg Institute of Health, Strassen, Luxembourg"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Tipple","sequence":"additional","affiliation":[{"name":"Drugs for Neglected Diseases initiative, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Fraisse","sequence":"additional","affiliation":[{"name":"Drugs for Neglected Diseases initiative, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Silvestre-Sousa","sequence":"additional","affiliation":[{"name":"Instituto Nacional de Infectologia Evandro Chagas, Funda\u00e7\u00e3o Oswaldo Cruz, Rio de Janeiro, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Sosa-Estani","sequence":"additional","affiliation":[{"name":"Drugs for Neglected Diseases initiative, Rio de Janeiro, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda-Jes\u00fas","family":"Pinazo","sequence":"additional","affiliation":[{"name":"Drugs for Neglected Diseases initiative, Rio de Janeiro, Brazil"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,9,30]]},"reference":[{"key":"2025093002151548000_15.9.e098079.1","unstructured":"World Health Organization . Chagas disease in latin america: an epidemiological update based on 2010 estimates. In: Weekly Epidemiological Record. 7. World Health Organization, 2015."},{"key":"2025093002151548000_15.9.e098079.2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(13)70002-1"},{"key":"2025093002151548000_15.9.e098079.3","unstructured":"Elimination of mother-to-child transmission of hiv, syphilis, perinatal hepatitis b, and congenital chagas disease - opas\/oms | organiza\u00e7\u00e3o pan-americana da sa\u00fade."},{"key":"2025093002151548000_15.9.e098079.4","doi-asserted-by":"crossref","DOI":"10.1186\/s12889-019-7248-5","article-title":"Building an innovative Chagas disease program for primary care units, in an urban non- endemic city","volume":"19","author":"Pereiro","year":"2019","journal-title":"BMC Public Health"},{"key":"2025093002151548000_15.9.e098079.5","unstructured":"Pan American health organization: guidelines for the diagnosis and treatment of chagas disease. Washington, DC PAHO; 2019."},{"key":"2025093002151548000_15.9.e098079.6","doi-asserted-by":"publisher","DOI":"10.1590\/S0037-86822007000100001"},{"key":"2025093002151548000_15.9.e098079.7","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-144-10-200605160-00006"},{"key":"2025093002151548000_15.9.e098079.8","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0006814","article-title":"Beneficial effects of benznidazole in Chagas disease: NIH SaMi-Trop cohort study","volume":"12","author":"Cardoso","year":"2018","journal-title":"PLoS Negl Trop Dis"},{"key":"2025093002151548000_15.9.e098079.9","first-page":"939","article-title":"Benznidazole and Posaconazole in Eliminating Parasites in Asymptomatic T","volume":"69","author":"Morillo","year":"2017","journal-title":"Cruzi Carriers The STOP-CHAGAS Trial"},{"key":"2025093002151548000_15.9.e098079.10","first-page":"1295","article-title":"BENEFIT Investigators","volume":"373","author":"Marin-Neto J","year":"2015","journal-title":"Randomized Trial of Benznidazole for Chronic Chagas\u2019 Cardiomyopathy N Engl J Med"},{"key":"2025093002151548000_15.9.e098079.11","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2018.1509704"},{"key":"2025093002151548000_15.9.e098079.12","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0002907","article-title":"Population pharmacokinetic study of benznidazole in pediatric Chagas disease suggests efficacy despite lower plasma concentrations than in adults","volume":"8","author":"Altcheh","year":"2014","journal-title":"PLoS Negl Trop Dis"},{"key":"2025093002151548000_15.9.e098079.13","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05018-14"},{"key":"2025093002151548000_15.9.e098079.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.trstmh.2012.07.010"},{"key":"2025093002151548000_15.9.e098079.15","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30844-6"},{"key":"2025093002151548000_15.9.e098079.16","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-052897","article-title":"New chemotherapy regimens and biomarkers for Chagas disease: the rationale and design of the TESEO study, an open-label, randomised, prospective, phase-2 clinical trial in the Plurinational State of Bolivia","volume":"11","author":"Alonso-Vega","year":"2021","journal-title":"BMJ Open"},{"key":"2025093002151548000_15.9.e098079.17","doi-asserted-by":"crossref","DOI":"10.1186\/s13063-020-4226-2","article-title":"Efficacy and safety assessment of different dosage of benznidazol for the treatment of Chagas disease in chronic phase in adults (MULTIBENZ study): study protocol for a multicenter randomized Phase II non-inferiority clinical trial","volume":"21","author":"Molina-Morant","year":"2020","journal-title":"Trials"},{"key":"2025093002151548000_15.9.e098079.18","doi-asserted-by":"crossref","DOI":"10.1186\/s12978-020-00972-1","article-title":"Short-course Benznidazole treatment to reduce Trypanosoma cruzi parasitic load in women of reproductive age (BETTY): a non-inferiority randomized controlled trial study protocol","volume":"17","author":"Cafferata","year":"2020","journal-title":"Reprod Health"},{"key":"2025093002151548000_15.9.e098079.19","doi-asserted-by":"crossref","DOI":"10.1186\/s13063-019-3423-3","article-title":"Nifurtimox versus benznidazole or placebo for asymptomatic Trypanosoma cruzi infection (Equivalence of Usual Interventions for Trypanosomiasis - EQUITY): study protocol for a randomised controlled trial","volume":"20","author":"Villar","year":"2019","journal-title":"Trials"},{"key":"2025093002151548000_15.9.e098079.20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0010827","article-title":"Comparing in vivo bioluminescence imaging and the Multi-Cruzi immunoassay platform to develop improved Chagas disease diagnostic procedures and biomarkers for monitoring parasitological cure","volume":"16","author":"Francisco","year":"2022","journal-title":"PLoS Negl Trop Dis"},{"key":"2025093002151548000_15.9.e098079.21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0004596","article-title":"Development of a Novel Multiplex Immunoassay Multi-cruzi for the Serological Confirmation of Chagas Disease","volume":"10","author":"Granjon","year":"2016","journal-title":"PLoS Negl Trop Dis"},{"key":"2025093002151548000_15.9.e098079.22","doi-asserted-by":"crossref","DOI":"10.1590\/0037-8682-0171-2021","article-title":"The CUIDA Chagas Project: towards the elimination of congenital transmission of Chagas disease in Bolivia, Brazil, Colombia, and Paraguay","volume":"55","author":"Sousa","year":"2022","journal-title":"Rev Soc Bras Med Trop"},{"key":"2025093002151548000_15.9.e098079.23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0002000","article-title":"Analytical Performance of a Multiplex Real-Time PCR Assay Using TaqMan Probes for Quantification of Trypanosoma cruzi Satellite DNA in Blood Samples","volume":"7","author":"Duffy","year":"2013","journal-title":"PLoS Negl Trop Dis"},{"key":"2025093002151548000_15.9.e098079.24","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0000931","article-title":"International study to evaluate PCR methods for detection of Trypanosoma cruzi DNA in blood samples from Chagas disease patients","volume":"5","author":"Schijman","year":"2011","journal-title":"PLoS Negl Trop Dis"},{"key":"2025093002151548000_15.9.e098079.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmoldx.2015.04.010"},{"key":"2025093002151548000_15.9.e098079.26","doi-asserted-by":"crossref","unstructured":"Parrado R , Ramirez JC , de la Barra A , et al . Usefulness of Serial Blood Sampling and PCR Replicates for Treatment Monitoring of Patients with Chronic Chagas Disease. Antimicrob Agents Chemother 2019;63. doi:10.1128\/AAC.01191-18","DOI":"10.1128\/AAC.01191-18"},{"key":"2025093002151548000_15.9.e098079.27","doi-asserted-by":"crossref","first-page":"101156","DOI":"10.1016\/j.lanmic.2025.101156","article-title":"Quantifying anti-trypanosomal treatment effects in chronic indeterminate Chagas disease: a secondary analysis of individual patient data from two proof-of-concept trials","volume":"8","author":"Watson","year":"2025","journal-title":"Lancet Microbe"},{"key":"2025093002151548000_15.9.e098079.28","unstructured":"WHO . Mental disorders. World Health Organization; 2023. Available: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/mental-disorders"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2024-098079","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T09:16:32Z","timestamp":1759223792000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2024-098079"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":28,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9,30]]},"published-print":{"date-parts":[[2025,9]]}},"alternative-id":["10.1136\/bmjopen-2024-098079"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2024-098079","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9]]}}}